Finance entity
markets accounts for 9 of the 11 tracked stories, while 1 other category carries the remainder. Wall Street Zen is the most frequent co-covered peer, appearing in 6 of the 11 tracked stories. Sentiment skews less negative than the wider beat, at 0% negative against 18% across all 788 Finance stories in the same window.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets accounts for 9 of the 11 tracked stories, while 1 other category carries the remainder. Wall Street Zen is the most frequent co-covered peer, appearing in 6 of the 11 tracked stories. Sentiment skews less negative than the wider beat, at 0% negative against 18% across all 788 Finance stories in the same window. The 48-day window averages about 1.6 stories each week. The busiest single day carried 3. Each story carries 2.1 original sources on average, compared with 2.3 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.8. This profile follows 11 Finance stories mentioning MarketBeat.com across the period from August 13, 2026 to September 29, 2026.
Computed from the 11 stories linked to this entity, with beat comparisons drawn from all 788 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat.com. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
Wall Street Zen downgrades to Hold
Wall Street Zen cut both Klaviyo and Oceaneering International from Buy to Hold in Saturday research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
OII insider sale
SVP Christopher J. Dyer sold 1,200 OII shares at an average price of $47.65 for $57,180.
B. Riley trims BRSP target
B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating.
JonesTrading reiterates BRSP buy
JonesTrading reissued a buy rating and a $6.50 price objective on BrightSpire Capital.
Weiss upgrades OII
Weiss Ratings raised OII from Buy (B-) to Buy (B).
BrightSpire reports Q2 earnings
BRSP posted EPS of $0.13, missing the $0.15 consensus, with revenue of $48.70 million.
Barclays lifts OII target
Barclays increased its OII price objective from $39.00 to $47.00 with an Equal Weight rating.
James Frew buys AMPY shares
Insider James Frew acquired 25,000 Amplify Energy shares at an average cost of $3.95 per share.
Citigroup raises OII target
Citigroup raised its Oceaneering target from $35.00 to $40.00 with a Neutral rating.
Weiss lowers BrightSpire Capital
Weiss Ratings lowered BRSP from hold (c-) to sell (d+).
TD Cowen lifts OII target
TD Cowen raised its Oceaneering International price target from $34.00 to $36.00 with a Hold rating.
BTIG upgrades BrightSpire Capital
BTIG Research raised BRSP from neutral to buy and set a $7.00 price target.
Susquehanna lifted Accenture's price target from $140 to $153 but kept a Neutral rating, implying the stock could fall 12.98% from its $174.40 open. The move leaves Susquehanna well below the $200.52 consensus target, highlighting sharp disagreement among analysts on ACN's fair value.
Source: dailypolitical.com · Americanbankingnews
Wall Street Zen upgraded CVS Health to strong-buy, adding to 22 buy ratings and a $107.24 consensus target that implies 23% upside from Friday's $87.02 open. Macy's and NewJersey Resources were also upgraded, signaling broad analyst optimism.
Source: dailypolitical.com · themarketsdaily.com
Nitto Denko offers a 1.1% dividend yield and 16.8% payout ratio against a 0.9% yielding, 33.9% payout peer group. But analysts see less upside for NDEKY than the industry's 23.95% average, reflecting a value-versus-growth split.
Source: Zolmax · Watch List News
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Analysts remain mostly bullish on RTX and GE Vernova after July earnings, lifting price targets to as high as $250 and $1,338 respectively. Friday's gains came on unusually light volume, raising questions about conviction. Finance readers get a breakdown of target upside, valuation, and risk metrics.
Source: tickerreport.com · dailypolitical.com
A MarketBeat-based comparison shows ZOOZ Power offers 85.01% implied upside versus Regal Rexnord's 39.62%, but the ownership and volatility profiles point in opposite directions. Regal Rexnord wins on 9 of 12 factors, yet ZOOZ's insider-heavy ownership and analyst target suggest a higher-reward, lower-liquidity opportunity.
Source: Ticker Report · Watch List News
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
MarketBeat.com is linked from 11 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
